Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells
Activating mutations in KRAS are the hallmark genetic alterations in pancreatic ductal adenocarcinoma (PDAC) and the key drivers of its initiation and progression. Longstanding efforts to develop novel KRAS inhibitors have been based on the assumption that PDAC cells are addicted to activated KRAS,...
Main Authors: | Chen, Pan-Yu, Muzumdar, Mandar, Dorans, Kimberly, Robbins, Rebecca, Bhutkar, Arjun, Del Rosario, Amanda M, Mertins, Philipp, Qiao, Jana, Schafer, Anette Claudia, Gertler, Frank, Carr, Steven A, Jacks, Tyler E |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biology |
Format: | Article |
Language: | English |
Published: |
American Association for Cancer Research (AACR)
2020
|
Online Access: | https://hdl.handle.net/1721.1/124410 |
Similar Items
-
Survival of pancreatic cancer cells lacking KRAS function
by: Noll, Elisa M., et al.
Published: (2017) -
Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
by: Dorans, Kimberly, et al.
Published: (2017) -
Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer
by: Tao, Zhimin, et al.
Published: (2022) -
Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer
by: Tao, Zhimin, et al.
Published: (2021) -
Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma
by: Chung, Katherine Minjee, et al.
Published: (2021)